Press Conference: Phase 2 of NA-931, an oral quadruple receptor agonist for the treatment of obesity

Registration for Biomed Press Conference- at ADA on Phase 2 results of NA-931

June 23, 2025 at 10:30 AM Chicago (CST) - Free Registration
Title*

ProfessorDr.Mr.Mrs.Ms.
Name*

First NameLast Name
Organization/ University/Company*
Job position*
Your Job function*

Industry researcherAcademic researcherNews/Media reporterBiotech executivePhD/post doctoral studentOther
Address*

University/ CompanyHome Address
Address*

Street Address

Street Address Line 2

CityState/ Province

Zip Code/Postal CodeCountry
Phone Number*

Area CodePhone Number
Email*
example@example.com
Confirm email*
example@example.com
Your questions or comments to the panelists (optional)
Should be Empty: